Skip to main content
Skip to main navigation
Invalid credentials.
Search for :
Product Development Strategy
Early Clinical Development
Phase I/IIa Clinical Trials
Phase II/III Clinical Trials
Interventional Phase IIIb/Phase IV Clinical Trials
Observational Research & Registries
Product Launch & Management
Market Access Solutions
Strategic Sales Outsourcing
Biopharmaceutical R&D
Biopharmaceutical Sales & Marketing
Biosimilars
Healthcare Payers & Providers
Medical Device & Diagnostics
Public Health & Government
Cardiovascular
Central Nervous System
Diabetes & Endocrinology
Infectious Diseases
Internal Medicine
Oncology
Early Phase Oncology
Translational Oncology
Pediatrics
Public Health Interest
Vaccines
Other Therapeutic Areas
Our Focus
Our Values
Our Heritage
Our Perspectives
Our Leadership
Ethics & Compliance
Investors
Global Locations
Facebook Twitter LinkedIn YouTube
Local Resources: Central Lab, Clinical, Commercial Project Management, Regulatory
Operating since: 1999
Patients enrolled: 25,000 - 50,000 in Asia (2004-2008)
Studies 200-500 in Asia (2004-2008)
Workforce: 2,500 - 5,000 in Asia (2004-2008)
Go to China
Go to Hong Kong
Go to India
Go to Indonesia
Go to Japan
Go to Pakistan
Outstanding access to patients in the Middle East region with a population of over 200 million means this is an important emerging region for the biopharmaceutical industry and Quintiles has a proven track record of rapid patient enrollment with high patient retention rates. Read fact sheet
This Economist Intelligence Unit study, sponsored by Quintiles, looks at China’s growing pharmaceutical market and its implications for the global life sciences sector. Read white paper